Literature DB >> 7758517

Early detection of doxorubicin and daunorubicin cardiotoxicity by echocardiography: diastolic versus systolic parameters.

K Schmitt1, G Tulzer, M Merl, G Aichhorn, A Grillenberger, G Wiesinger, G Hofstadler.   

Abstract

Doxorubicin and daunorubicin are effective anticancer agents in children, however, their therapeutic value is limited by myocardial cardiotoxicity. In 14 children (median age 5.0 years, range 3-12) prospective studies were performed using pulsed Doppler echocardiography to assess the changes in left ventricular systolic and diastolic filling dynamics. None of these children developed cardiomyopathy. M-mode echocardiographic systolic parameters and Doppler transmitral flow velocities were analysed at baseline, after a cumulative anthracycline dose of 138 +/- 26 mg/m2 (second examination) and after 240 +/- 15 mg/m2 (third examination). At the second examination the acceleration time/ejection time ratio was significantly reduced (P < 0.01), but this was no longer evident at the third examination. There was no significant change of peak velocity over aortic valve, pre-ejection period and change of velocity over time. In contrast, three diastolic parameters changed significantly; the late over early inflow velocity (P < 0.05), mitral valve late time velocity integral (P < 0.01 at the second and P < 0.05 at the third examination) and the ratio A-TVI/TVI (P < 0.025 and P < 0.01). At the third examination the velocity of the A wave was also significantly increased. CONCLUSION In anthracycline treated children left ventricular diastolic function deteriorates before systolic function. Diastolic function parameters should be used rather than systolic parameters to monitor these patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758517     DOI: 10.1007/BF01954271

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  20 in total

1.  Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer.

Authors:  A M Goorin; A R Chauvenet; A R Perez-Atayde; J Cruz; R McKone; S E Lipshultz
Journal:  J Pediatr       Date:  1990-01       Impact factor: 4.406

Review 2.  Age-related adriamycin cardiotoxicity in children.

Authors:  C B Pratt; J L Ransom; W E Evans
Journal:  Cancer Treat Rep       Date:  1978-09

3.  Effect of imaging view and sample volume location on evaluation of mitral flow velocity by pulsed Doppler echocardiography.

Authors:  J M Gardin; A Dabestani; K Takenaka; M K Rohan; M Knoll; D Russell; W L Henry
Journal:  Am J Cardiol       Date:  1986-06-01       Impact factor: 2.778

4.  Determination of parameters of left ventricular diastolic filling with pulsed Doppler echocardiography: comparison with cineangiography.

Authors:  R Rokey; L C Kuo; W A Zoghbi; M C Limacher; M A Quinones
Journal:  Circulation       Date:  1985-03       Impact factor: 29.690

5.  Ventricular performance measured during ejection: Studies in patients of the rate of change of ventricular power.

Authors:  P D Stein; H N Sabbah
Journal:  Am Heart J       Date:  1976-05       Impact factor: 4.749

6.  Anthracycline cardiomyopathy monitored by morphologic changes.

Authors:  M E Billingham; J W Mason; M R Bristow; J R Daniels
Journal:  Cancer Treat Rep       Date:  1978-06

7.  [Long-term study of anthracycline-induced cardiomyopathy in children and adolescents].

Authors:  H Koch; L Schmitz; K Brockmeier; R Hartmann; G Bein; G Henze
Journal:  Klin Padiatr       Date:  1991 Jul-Aug       Impact factor: 1.349

8.  Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.

Authors:  M R Bristow; J W Mason; M E Billingham; J R Daniels
Journal:  Am Heart J       Date:  1981-10       Impact factor: 4.749

9.  Doppler echocardiographic assessment of left ventricular filling dynamics in patients with coronary heart disease and normal systolic function.

Authors:  H F Kuecherer; K Ruffmann; E Schaefer; W Kuebler
Journal:  Eur Heart J       Date:  1988-06       Impact factor: 29.983

10.  Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study.

Authors:  C P Appleton; L K Hatle; R L Popp
Journal:  J Am Coll Cardiol       Date:  1988-08       Impact factor: 24.094

View more
  6 in total

1.  Tei index in adult patients submitted to adriamycin chemotherapy: failure to predict early systolic dysfunction. Diagnosis of adriamycin cardiotoxicity.

Authors:  Luis E Rohde; Alexandre Baldi; Cristiane Weber; Guilherme Geib; Nicolle Gollo Mazzotti; Marlon Fiorentini; Murilo Roggia; Rodrigo Pereira; Nadine Clausell
Journal:  Int J Cardiovasc Imaging       Date:  2006-09-14       Impact factor: 2.357

Review 2.  Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging.

Authors:  Gurusher Singh Panjrath; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2006 May-Jun       Impact factor: 5.952

3.  Usefulness of myocardial performance index in multiple sclerosis mitoxantrone-induced cardiotoxicity.

Authors:  Paolo Pattoneri; Giovanna Pelà; Enrico Montanari; Ilaria Pesci; Paolo Moruzzi; Alberto Montanari
Journal:  Heart Asia       Date:  2012-01-01

4.  Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer.

Authors:  Jon M Appel; Benny V Jensen; Dorte L Nielsen; Marianne Ryberg; Bo Zerahn
Journal:  Int J Cardiovasc Imaging       Date:  2009-10-13       Impact factor: 2.357

5.  Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computed tomography.

Authors:  Kathleen L Gabrielson; Greta S P Mok; Srihdar Nimmagadda; Djahida Bedja; Scott Pin; Allison Tsao; Yuchuan Wang; Dhrtti Sooryakumar; S Jianhua Yu; Martin G Pomper; Benjamin M W Tsui
Journal:  Mol Imaging       Date:  2008 May-Jun       Impact factor: 4.488

6.  CaMKII activation participates in doxorubicin cardiotoxicity and is attenuated by moderate GRP78 overexpression.

Authors:  Henrike Tscheschner; Eric Meinhardt; Philipp Schlegel; Andreas Jungmann; Lorenz H Lehmann; Oliver J Müller; Patrick Most; Hugo A Katus; Philip W Raake
Journal:  PLoS One       Date:  2019-04-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.